Development of Novel Activatable Theranostic Nanoparticles for combined Cancer MR

开发用于联合癌症 MR 的新型可激活治疗诊断纳米颗粒

基本信息

批准号：
8636819
负责人：
Heike Elizabeth Daldrup-Link
金额：
$ 20.95万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-01 至 2016-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8636819
关键词：
Address Adverse effects Antineoplastic Agents Biological Markers Biosensor Blood Vessels Chemotherapy-Oncologic Procedure Cleaved cell Development Diagnostic Dose Dose-Limiting Drug Delivery Systems Drug Monitoring Endothelial Cells Endothelium Enzymes Evaluation Extravasation FDA approved Family Goals Hair High Prevalence Human Image In Vitro Investigation Lead Magnetic Resonance Magnetic Resonance Imaging Malignant Neoplasms Matrix Metalloproteinases Mediating Membrane Mission Monitor Mouse Mammary Tumor Virus National Cancer Institute National Institute of Biomedical Imaging and Bioengineering Nature Nausea Neoplasms in Vascular Tissue Normal tissue morphology Organ Outcome Peptide Hydrolases Peptides Permeability Pharmaceutical Preparations Pharmacodynamics Play Positioning Attribute Prevalence Prodrugs Radiation Regimen Research Role Signal Transduction Site Specificity Starvation System Technology Testing Therapeutic Therapeutic Agents Therapeutic Effect Therapeutic Index Time Tissues Toxic effect Transgenic Organisms Translating Treatment Efficacy Tumor Tissue Vascular Permeabilities Visceral Weight base bioimaging biomaterial compatibility cancer cell cancer therapy cancer type cell behavior clinical application clinical decision-making cytotoxic design disability improved in vivo iron oxide killings malignant breast neoplasm mouse model nanocarrier nanoparticle nanoscale neoplastic cell non-invasive monitor novel novel strategies outcome forecast overexpression public health relevance research and development response theranostics therapeutic target tool tumor tumor eradication tumor microenvironment

项目摘要

DESCRIPTION (provided by applicant): This study is in response to the mission of the National Institute of Biomedical Imaging and Bioengineering ("Research and development of nano-scale technologies for biomedical imaging") and the National Cancer Institute ("cancer theranostics with improved targeting, biocompatibility and imaging contrast capability"). A major issue with current cancer therapy is the prevalence of undesired dose-limiting activity upon non-cancerous tissues and organs. This is further compounded by limited ability in monitoring drug delivery, pharmacodynamics and therapeutic response in vivo. To address the urgent need for novel approaches to selectively targeting therapeutics to tumor, we propose to develop and test new, activatable, "theranostic" (combined therapeutic and diagnostic) nanoparticles that release the potent therapeutic drug azademethylcolchicine after cleavage by specific tumor enzymes (matrix metalloproteinases, MMP-14), thereby leading to selective toxic effects in MMP-14 expressing tumors, but not visceral organs. In addition, the iron oxide core of the nanoparticles can be detected with MR imaging, thereby enabling in vivo drug tracking. Thus, the major goal of our project is to develop novel tumor-enzyme activatable theranostic nanoparticles (TNPs), which exert selective toxic effects in MMP-14 expressing tumors, but not normal organs, and which enable real-time monitoring of drug accumulation and localization at tumors with Magnetic Resonance (MR) imaging. Realizing this goal will lead to substantially improved efficacy of cancer therapies, and allow guiding personalized therapy regimens via direct in vivo drug tracking and therapeutic response monitoring with MR imaging. The approach relies on the high prevalence of MMP-14 in a large variety of breast cancers and other cancers, a proven MMP-14 activatable prodrug strategy, and a nanocarrier platform based on FDA-approved superparamagnetic iron oxide nanoparticles. We hypothesize that our TNPs will be converted from a non-toxic to an active therapeutic agent within MMP-14 expressing tumors, releasing the potent therapeutic drug azademethylcolchicine, and inducing a significant antitumor effect, whilst avoiding toxic side effects to normal tissues. In addition, we postulate that the iron oxide nanoparticle moiety will allow real-time monitoring of drug accumulation and localization at tumors with MR imaging. If successful, the proposed novel, multifunctional TNPs hold the potential to substantially improving therapeutic efficacy and monitoring whilst simultaneously reducing dose-limiting toxicities, thereby increasing the therapeutic index. Our investigations could be in principle readily translated to clinical applications, may directly impact clinical decision-making, and ultimately, help to improve and tailor individualized therapeutic options. The proposed concept would have broad applications and could be extended to a variety of other cancer types.

描述（由申请人提供）：本研究是为了响应国家生物医学成像和生物工程研究所（“生物医学成像纳米级技术的研究和开发”）和国家癌症研究所（“改进癌症治疗诊断学”的使命）靶向、生物相容性和成像对比能力”）。当前癌症治疗的一个主要问题是对非癌组织和器官普遍存在不期望的剂量限制活性。监测体内药物递送、药效学和治疗反应的能力有限，进一步加剧了这一问题。为了满足对选择性靶向肿瘤治疗的新方法的迫切需求，我们建议开发和测试新的、可激活的、“治疗诊断”（组合治疗和诊断）纳米颗粒，这些纳米颗粒在被特定肿瘤酶（基质）裂解后释放出有效的治疗药物氮杂甲基秋水仙碱。金属蛋白酶，MMP-14），从而导致对表达 MMP-14 的肿瘤产生选择性毒性作用，但不会对内脏器官产生选择性毒性作用。此外，纳米颗粒的氧化铁核心可以通过磁共振成像进行检测，从而实现体内药物追踪。因此，我们项目的主要目标是开发新型肿瘤酶可激活的治疗诊断纳米颗粒（TNP），它对表达 MMP-14 的肿瘤（而非正常器官）发挥选择性毒性作用，并且能够实时监测药物蓄积和通过磁共振 (MR) 成像对肿瘤进行定位。实现这一目标将大大提高癌症治疗的疗效，并允许通过直接体内药物跟踪和磁共振成像治疗反应监测来指导个性化治疗方案。该方法依赖于 MMP-14 在多种乳腺癌和其他癌症中的高患病率、经过验证的 MMP-14 可激活前药策略以及基于 FDA 批准的超顺磁性氧化铁纳米颗粒的纳米载体平台。我们假设，我们的 TNP 将在表达 MMP-14 的肿瘤内从无毒转化为活性治疗剂，释放有效的治疗药物氮杂甲基秋水仙碱，并诱导显着的抗肿瘤作用，同时避免对正常组织的毒副作用。此外，我们假设氧化铁纳米颗粒部分将允许通过磁共振成像实时监测肿瘤中的药物积累和定位。如果成功，所提出的新型多功能 TNP 有可能显着提高治疗效果和监测，同时减少剂量限制毒性，从而提高治疗指数。我们的研究原则上可以很容易地转化为临床应用，可能直接影响临床决策，并最终帮助改进和定制个体化治疗方案。所提出的概念将具有广泛的应用，并且可以扩展到多种其他癌症类型。